FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
Executive Summary
FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed
You may also be interested in...
BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence
Boehringer Ingelheim GmbH saw an opportunity to gather more and better head-to-head data for anti-diabetic Tradjenta in its post-market cardiovascular outcomes trial, but FDA couldn't picture a better comparator than gold-standard placebo.
BI’s Tradjenta Lesson: Don’t Try To Use CV Trial To Score Head-To-Head Efficacy Evidence
Boehringer Ingelheim GmbH saw an opportunity to gather more and better head-to-head data for anti-diabetic Tradjenta in its post-market cardiovascular outcomes trial, but FDA couldn't picture a better comparator than gold-standard placebo.
Korea FDA Sends Precautionary Notice To Doctors For Diabetes Drugs Containing Rosiglitazone
SEOUL - South Korea's Food and Drug Administration issued its second precautionary notice to doctors, calling for caution in prescribing diabetes drugs containing rosiglitazone, including GlaxoSmithKline's Avandia and Avandaryl, Sanofi Aventis' Amavan, and local Korean Yuhan Corp.'s generic rosiglitazone